LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease worldwide. The companys endovascular products include LeverEdge contrast injector for injection of contrast media into blood vessels; TAArget thoracic stent graft for use in the endovascular repair of thoracic aortic aneurysm and dissection; the UnBalloon non-occlusive modeling catheter for improvement in the seal of aortic stent grafts; and VascuTape radiopaque tape for improvement in precision of vascular and endovascular procedures. Its vascular products consist of AlboGraft vascular grafts for in bypass and replacement procedures; AlboSure and XenoSure vascular patches for use in closing incisions in a blood vessel; AnastoClip vessel closure system for attaching blood vessels primarily for dialysis access; EndoRE remote endarterectomy devices for removal of blockages in the arteries of the leg; expandable LeMaitre valvulotome for destruction of vein valves to create vein bypass grafts; InvisiGrip vein stripper for single-incision removal of varicose veins; LeMaitre balloon catheters for removal of blood clots, occlusion, and facilitation of blood flow; and Pruitt-Inahara, Pruitt F3, and Flexcel carotid shunts for facilitating blood flow to brain during carotid plaque removal.

LeMaitre Vascular companys products in general surgery category comprise reddick cholangiogram catheter for introduction of dye into the cystic duct; and OptiLock implantable port for central venous infusion of drugs and nutrients. In addition, LeMaitre distributes Powerlink system, a bifurcated abdominal stent graft, as well as engages in private label manufacturing. It sells its products through direct sales force and a network of distributors. LeMaitre Vascular was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.